Tag: Orphan Drug
FDA Grants Nohla Therapeutics’ Cell Therapy Dilanubicel Orphan Drug Designation for HSCT
Nohla Therapeutics, headquartered in Seattle, is a leading developer of “off-the shelf” cell therapies for patients with cancer and other diseases. Nohla’s proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs....
